ContentsIntroductionRead (pg. 5)Groundbreaking Drug LaunchesRead (pg. 6)Semaglutide/ Cagrilintide (CagriSema)Read (pg. 7)Orforglipron (LY-3502970)Read (pg. 8)Oveporexton (TAK-861)Read (pg. 9)Zilganersen (ION1166998)Read (pg. 10)Hyaluronidase/Pembrolizumab (KEYTRUDA QLEX)Read (pg. 11)Elamipretide (Forzinity)Read (pg. 12)Paltusotine (Palsonify)Read (pg. 13)Remibrutinib (Rhapsido)Read (pg. 14)Elinzanetant (Lynkuet)Read (pg. 15)Sibeprenlimab (VOYXACT)Read (pg. 16)Notable mentionsRead (pg. 17)BiosimilarsRead (pg. 18)Semaglutide (Ozempic; Wegovy)Read (pg. 19)Pertuzumab (Perjeta)Read (pg. 20)Omalizumab (Xolair)Read (pg. 21)Patent Expirations and Market ImpactRead (pg. 22)Sitagliptin (Januvia)Read (pg. 23)Sugammadex (Bridion)Read (pg. 24)ConclusionRead (pg. 25)ReferencesRead (pg. 26)Pharma Insight Reportshttps://adisinsight.springer.com/insight-hub